These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553 [TBL] [Abstract][Full Text] [Related]
28. CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism? Macaluso M; Preskorn SH J Clin Psychopharmacol; 2011 Apr; 31(2):143-5. PubMed ID: 21346604 [No Abstract] [Full Text] [Related]
29. Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Gillman PK Hum Psychopharmacol; 2005 Jan; 20(1):61-2; author reply 63-4. PubMed ID: 15614840 [No Abstract] [Full Text] [Related]
30. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366 [TBL] [Abstract][Full Text] [Related]
31. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Sjöqvist F; Eliasson E Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719 [TBL] [Abstract][Full Text] [Related]
32. [The influence of clomipramine on CYP2D6 activity]. Szewczuk-Bogusławska M; Kiejna A; Grzesiak M; Beszłej JA; Chlebowska I; Orzechowska-Juzwenko K; Milejski P Psychiatr Pol; 2007; 41(2):243-9. PubMed ID: 17598433 [TBL] [Abstract][Full Text] [Related]
33. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism]. Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S Encephale; 2000; 26(1):62-7. PubMed ID: 10875063 [TBL] [Abstract][Full Text] [Related]
34. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Cacabelos R Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277 [TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetics and psychoactive drug therapy: ready for the patient? Steimer W Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233 [TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Porcelli S; Fabbri C; Spina E; Serretti A; De Ronchi D Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1101-15. PubMed ID: 21736534 [TBL] [Abstract][Full Text] [Related]
40. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Schosser A; Kasper S Int Clin Psychopharmacol; 2009 Nov; 24(6):277-88. PubMed ID: 19738481 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]